STOCK TITAN

Sonnet Biotherapeutc Hldng Inc - SONN STOCK NEWS

Welcome to our dedicated page for Sonnet Biotherapeutc Hldng news (Ticker: SONN), a resource for investors and traders seeking the latest updates and insights on Sonnet Biotherapeutc Hldng stock.

Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) is a clinical-stage biotechnology innovator developing targeted immunotherapies through its proprietary FHAB platform. This page serves as the definitive source for verified company announcements, including clinical trial updates, regulatory milestones, and strategic developments in immuno-oncology.

Investors and researchers will find timely updates on SONN's pipeline progress, including its lead candidates targeting cancer and immune-mediated conditions. Our curated news collection features press releases about FHAB technology advancements, partnership announcements, and financial disclosures – all essential for tracking this innovative biotech's trajectory.

The repository systematically organizes updates across key categories: new patent filings, preclinical data publications, Phase 1 trial results, and executive team developments. Each entry maintains strict editorial standards to ensure compliance with financial reporting regulations.

For those monitoring advancements in bispecific antibody therapies and tumor microenvironment modulation, this resource offers structured access to SONN's scientific and corporate developments. Bookmark this page for efficient tracking of how the company's platform-based approach translates to clinical progress and strategic positioning within the competitive oncology landscape.

Rhea-AI Summary

Sonnet BioTherapeutics (NASDAQ:SONN) has appointed Stephen J. McAndrew, Ph.D., as Chief Business Officer, effective February 17, 2025. Dr. McAndrew, who brings over 30 years of experience in biologics transactions, has been serving as Vice President and Senior Vice President of Business Development at Sonnet, managing partnering strategy, research partnerships, and the global IP portfolio.

The appointment aims to strengthen Sonnet's business development initiatives as their FHAB assets advance in clinical development. Dr. McAndrew's extensive experience includes senior roles at Oncobiologics (now Outlook Therapeutics) and Bristol-Myers Squibb, where he managed business development, licensing, and marketing functions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
management
-
Rhea-AI Summary

Sonnet BioTherapeutics (NASDAQ: SONN) has reported key developments in its clinical programs and financial results for Q1 FY2025. The company completed the Phase 1 SB101 trial dose escalation for SON-1010, showing stable disease in 48% of evaluable monotherapy patients and one partial response with 45% tumor reduction. Clinical trials are progressing for SON-1010 combinations with Atezolizumab and trabectedin.

The company secured a licensing agreement with Alkem Laboratories for SON-080 in India and reported Q1 FY2025 financial results with a net loss of $3.2 million ($1.56 per share), compared to $1.2 million loss in Q1 FY2024. Cash position stands at $4.9 million as of December 31, 2024. The company recently raised $3.9 million through a registered direct offering.

Leadership changes include Stephen McAndrew's promotion to Chief Business Officer and Donald Griffith's appointment as new CFO, replacing Jay Cross.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
-
Rhea-AI Summary

Sonnet BioTherapeutics (NASDAQ: SONN) has secured European Patent No. EP3583125 B1 for its Fully Human Albumin Binding (FHAB®) technology, effective until February 20, 2038. The patent covers therapeutic fusion proteins utilizing FHAB for tumor targeting and extended pharmacokinetics.

The company's FHAB platform consists of a single, fully human construct with high affinity to bind to human albumin, providing an off-the-shelf solution for rapid therapeutic biologics development. This EU patent adds to Sonnet's existing global IP protection in China, Japan, Russia, and New Zealand.

Preclinical studies have demonstrated that FHAB-derived drug candidates show extended pharmacokinetics, enhanced tumor payload delivery, and improved efficacy compared to wild type cytokines. The platform enables both mono- and bi-functional mechanisms of action, potentially allowing for biological synergy between cytokines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.42%
Tags
none
Rhea-AI Summary

Sonnet BioTherapeutics (NASDAQ: SONN), a clinical-stage company focused on developing targeted immunotherapeutic drugs, has announced its participation in an upcoming healthcare investment webinar. Dr. Pankaj Mohan, the company's CEO, will present at the LIVE! with Webull Corporate Connect: Healthcare Investment Webinar on Wednesday, January 29th, 2025 at 2:40 PM ET.

The virtual biotech investment event provides an opportunity for investors to learn more about Sonnet's developments in the immunotherapeutics space. Interested participants can access the presentation through the provided registration link.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.87%
Tags
conferences
-
Rhea-AI Summary

Sonnet BioTherapeutics (NASDAQ:SONN) announced the expansion of its Phase 1 SB101 clinical study of SON-1010 to evaluate its combination with trabectedin in soft-tissue sarcoma patients. The expansion follows successful monotherapy dose escalation and will explore SON-1010's immune-oncology impact at the maximum tolerated dose of 1200 ng/kg.

The study will enroll up to 18 patients with unresectable, metastatic liposarcoma or leiomyosarcoma. Enrollment is expected to complete in H1 2025, with topline safety data anticipated in H2 2025. The trial's primary outcomes include safety, tolerability, pharmacokinetics, and pharmacodynamics of SON-1010.

SON-1010, Sonnet's proprietary version of IL-12, is configured using the FHAB platform to extend half-life and bioactivity. The company believes combining SON-1010 with trabectedin could enhance local immune response in the tumor microenvironment and potentially improve treatment outcomes for soft-tissue sarcoma patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Sonnet BioTherapeutics (NASDAQ: SONN) has released its latest CEO Corner segment featuring CEO Pankaj Mohan, Ph.D. The segment, published on the company's website, reviews key accomplishments for 2024 and outlines targeted value-driving milestones for 2025. The content will remain accessible on www.sonnetbio.com for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
none
Rhea-AI Summary

Sonnet BioTherapeutics (NASDAQ: SONN) reported fiscal year 2024 results with significant operational improvements. The company achieved a 37% reduction in total operating expenses compared to fiscal year 2023, with 43% of expenses covered by non-dilutive funding. Key developments include progress in clinical trials for SON-1010 in solid tumors and Platinum-Resistant Ovarian Cancer, and a licensing agreement for SON-080 in Diabetic Peripheral Neuropathy.

Financial results show R&D expenses decreased to $5.7M from $11.8M, and G&A expenses reduced to $6.1M from $7.1M year-over-year. The company had $0.1M cash on hand as of September 30, 2024, but secured additional funding through stock sales and tax incentives, projecting operations funded through July 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.97%
Tags
-
Rhea-AI Summary

Sonnet BioTherapeutics (NASDAQ:SONN) has announced a $3.9 million financing through a combination of registered direct offering and concurrent private placement. The company is selling 1,085,325 shares in the registered direct offering and 673,000 shares in the private placement, both priced at $2.23 per share. Each share comes with one warrant exercisable at $2.10 per share with a five-year term.

The transaction, expected to close around December 10, 2024, is being facilitated by Chardan as the exclusive placement agent. The proceeds will support research and development, clinical trials, and working capital needs. The offering is conducted under an effective S-3 registration statement, with the private placement shares being offered under Section 4(a)(2) of the Securities Act.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
private placement offering
-
Rhea-AI Summary

Sonnet BioTherapeutics (NASDAQ:SONN) has announced successful topline safety data from its Phase 1 SB101 trial of SON-1010 in advanced solid tumor patients. The maximum tolerated dose was established at 1200 ng/kg, with no dose-limiting toxicity or cytokine release syndrome observed.

Key findings include stable disease in 48% (10 of 21) of evaluable monotherapy patients at four months post-treatment initiation, including one patient at the maximum dose achieving a partial response with a 45% tumor reduction. Of 24 total patients, 17 (71%) showed stable disease at first follow-up. The safety profile has been favorable, with mostly mild adverse events reported.

The company is currently seeking partnership opportunities for later-stage development while continuing patient monitoring for long-term safety and tumor responses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
Rhea-AI Summary

Sonnet BioTherapeutics (NASDAQ: SONN) announced the publication of discovery and development data for SON-1010, their lead drug candidate, in Frontiers in Immunology. The research details their albumin-binding (FHAB®) technology combined with IL-12 for improved cancer treatment delivery.

The publication highlights the identification of molecules that bind to serum albumin across multiple species and pH ranges, leading to extended half-life and improved tumor targeting. Patents for FHAB and SON-1010 have been issued in major markets including the US, China, and Japan, expiring between 2038-2039.

The company is currently conducting a Phase 1 clinical trial of SON-1010 for advanced solid tumors, with safety data expected in Q4 2024. Additionally, SON-1010 is being evaluated in a Phase 1/2a study in combination with Roche's atezolizumab for Platinum-Resistant Ovarian Cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.18%
Tags
none
Sonnet Biotherapeutc Hldng Inc

Nasdaq:SONN

SONN Rankings

SONN Stock Data

3.86M
3.02M
1.58%
3.06%
3.03%
Biotechnology
Pharmaceutical Preparations
Link
United States
PRINCETON